TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022) TR1 – Luca Associates – Major Holdings in Shares (4 January 2022) TR1 – Lanstead – Major Holding in Shares Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price Collaboration with Imperial College London CORPORATE UPDATE – The Evolution of ImmuPharma EURONEXT DELISTING – Date: 18 October 2021 Prof. Sylviane Muller awarded prestigious Legion d’honneur.’ Corporate Update INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021 Director & PDMR Share Purchases Lanstead Capital TR1 FDA approves the Lupzuor™ PK study BOARD CHANGES BOARD APPOINTMENT 2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED FDA to agree on the Lupzuor™ PK study via a written response to “Type Notice of AGM and posting of Report & Accounts Director Retirement FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020 Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Appointment of Company Secretary Lanstead Capital TR1 ImmuPharma to present at Biotech Showcase™ Digital 2021 Total Share Capital Notification Grant of Share Options & PDMR dealing Conversion of Convertible Security Conversion of Convertible Security FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Total Share Capital Notification Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients Total Share Capital Notification Admission to trading on Euronext Growth Brussels of newly issued ordinary shares INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020 Share Subscription into Incanthera plc (“Incanthera”) Repayment of Convertible Security – Lind Global Macro Fund, LP Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Conversion of Convertible Security – Lind Global Macro Fund, LP Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund TR1 – Notification of major interest in shares by Lanstead Capital Director/PDMR Shareholding/TR-1 Placing to raise £6.5 million – update; related party transaction Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Placing to raise £6.5 million TR1 – Notification of major interest in shares by Lanstead Capital Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients 2020 Annual General Meeting – all Resolutions Passed Total Share Capital Notification ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline Notification of Change of Registered Office Address Notification of Change of AGM Venue Notice of AGM and posting of Report & Accounts TR1 – Notification of major interest in shares by Lanstead Capital ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka Audited Report & Accounts published on website FINAL RESULTS For the 12 months ended 31 December 2019 ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST) TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020 TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020 Subscription to raise £1.5 million to fund expansion of R&D pipeline Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial Admission to trading on Euronext Growth Brussels Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Dual listing on Euronext growth Brussels Share price volatility ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco TR1 – Notification of major interest in shareholdings ImmuPharma and Avion Pharmaceuticals sign exclusive licence INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 TR1 – Notification of Major Interest – Lanstead Capital Investors TR1 – Notification of Major Shareholding 2019 Annual General Meeting – All resolutions passed Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Subscription to raise £2.66 million Notice of AGM and posting of Report & Accounts FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018 Corporate Update Update on Nucant cancer programme IMM March 2019 Corporate Update Technology review published in Nature Communications Appointment of NOMAD Update on Corporate Activities Nominated Adviser Status Interim results announcement for the six months ended 30 June 2018 Standford Capital Partners and Si Capital are appointed as joint broker IMM September 2018 Corporate Update 2018 Annual General Meeting – All Resolutions Passed ImmuPharma announces positive pre-clinical data on its CIDP programme Annual Report and Accounts Posted to Shareholders Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort1 Holding in company Immupharma PLC confident on Lupuzor’s™ future Holding in company Holding in company Top line results of Lupuzor™ Pivotal Phase III Trial Appointment of Joint Broker Lupuzor™ ‘database lock’ confirmed for 6 April 2018 London Investor Evening – Monday 26 February 2018 @ 6pm Holding in Company Notification of Major Interest – Lanstead Increases Holding to over 5% Successful Placing to Raise £10 Million Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study Update on Lupuzor™ Pivotal Phase III Study ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company Successful Completion of Lanstead Sharing Agreement Interim Results Announcement for the six months ended 30 June 2017 ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions Update on Lupuzor™ Pivotal Phase III Study 2017 Annual General Meeting – All Resolutions Passed Annual General Meeting and Investor Presentation Notice of Annual General Meeting on 30 June 2017 at 10.30am Final Results Announcement for the twelve months ended 31 December 2016 Notification of full year results – 1st June 2017 Update on Lupuzor™ Pivotal Phase III Study Notification of Major Interest by Legal & General Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild Accelerated Bookbuild for the Issue of Equity Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment Change of Adviser Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed Update on Cancer Compound IPP-204106 ‘Nucant’ Notification of Major Interest by Legal & General TR1 Notification of Major Interest Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity Close of Accelerated Bookbuild INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016 Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting ImmuPharma Invited to Open an Additional Site in Mauritius ImmuPharma Invited to Open an Additional Site in Mauritius Northland Capital Appointed as Joint Broker Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Notification of Major Interest by Alto Invest to 4.15% Notification of Major Interest by Alto Invest PRELIMINARY RESULTS
for the year ended 31 December 2015 Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016 Notification of Preliminary Results. Date: 4 May 2016 First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Result of GM First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Placing and Subscription Raises £8.3 million Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients Lupuzor™ Phase III Pivotal Trial Update Board Change Tim McCarthy Appointed as Non-executive Chairman Interim Results Announcement for the six months ended 30 June 2015 Richard Warr ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™ Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™ ANNUAL GENERAL MEETING: 2015 Notice of Annual General Meeting: 29 May 2015 Preliminary Results Announcement for the year ended 31 December 2014 Dr Stéphane Méry Appointed as Non-Executive Director Cancer Update: IPP-204106 Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014 Lupuzor™ Gears Up To Start Pivotal Phase III trials ANNUAL GENERAL MEETING: 2014 ImmuPharma to access pioneering research in the Bordeaux region of France New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014 Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan ImmuPharma Sponsors the 2014 European Lupus Conference UPDATE: Cancer Programme IPP-204106 FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Appointment of Scientific Advisory Board ImmuPharma secures £50M financing facility for Lupuzor Phase III Immupharma gets Lupuzor research boost ImmuPharma Commences Trading on the Stuttgart Stock Exchange CNRS Confirms Lupuzor’sTM Effectiveness ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 ImmuPharma PLC Appoints Cenkos Securities as Joint Broker PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011 ImmuPharma PLC Appoints Head of Investor Relations ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger Interviews 2015: Lupuzor™ founder Professor Sylviane Muller Biotech Capital Conference: 6th February 2017 Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM) – April 2018 Dr Navid Malik, analyst at The Life Sciences Division talks to Directors Talk about the opportunities for Lupuzor™ – Sept 2019 Dr Navid Malik, Executive director and head of research at the Live Sciences Division who works with Immupharma discusses their recent licence Agreement for Lupuzor with Avion in US – 10 December 2019 ImmuPharma AGM 2021 – Investor Meet Company Presentation. 28 June 2021 ImmuPharma chair hails “successful” recruitment for Lupuzor™ trials ImmuPharma Chairman details £2.66m financing and open label extension study – July 2019 ImmuPharma Chairman explains why the Avion deal is so significant – Nov 2019 ImmuPharma chairman more optimistic on results for its Lupuzor drug – May 2018 ImmuPharma firmly committed to Lupuzor ahead of managed access programme – 18th Sept 2018 Immupharma Plc – A multi-billion dollar selling drug ImmuPharma PLC Chairman Tim McCarthy Progress, Opportunity, Milestones ImmuPharma PLC New Phase III Lupuzor Trial Data Positive – May 2018 Immupharma Plc On Track, Looking Good and Excited – 18th May 2017 ImmuPharma plc positive results and new initiation note – May 2019 Immupharma PLC still confident on Lupuzor’s future – 19th April 2018 ImmuPharma PLC to open Lupuzor™ trial site in Mauritius Immupharma raises £8.3mln for Lupuzor™ trials & early stage pipeline ImmuPharma’s CEO, Tim McCarthy, talks to Proactive Investor and presents the commercial strategy for the Company’s lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial – 17th August, 2021 ImmuPharma’s Chairman Tim McCarthy, and Tim Franklin, Chief Operating Officer join Proactive London’s Katie Pilbeam to explain the latest market update in respect of its late stage Lupus drug, Lupuzor – 10 February 2021 ImmuPharma’s chairman, Tim McCarthy, talks on widening of portfolio and focus on partnering opportunities – 13 April 2020 ImmuPharma’s McCarthy on phase III Lupuzor™ trials Interview with The Life Sciences Division’s executive director Dr Navid Malik – 5th June 2019 Interview with Tim McCarthy, Chairman of Immupharma – 19 Jan 2018 Investigators meeting, December 2015, Paris Lupuzor’s™ pivotal phase III trial Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc – 10 December 2019 Lupuzor™ could treat a number of diseases, says creator Navid Malik, of The Life Sciences Division talks to Proactive Investors on his investment thesis on ImmuPharma and its late stage drug asset, Lupuzor™ as it gears up to start Phase III trials in Lupus patients in H2 2021 – 18 February 2021 Navid Malik, The Life Sciences Division, talks to Andrew Scott at Proactive about ImmuPharma’s licencing deal with Avion and how it has re-ignited the potential for Lupuzor to be a blockbuster drug – 16 December 2019 Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update Proactive Investors interview with Chairman Tim McCarthy – May 2019 Q&A with Vadim Alexandre Head of Research at Northland Capital Partners Share Talk interview – 3 October 2018 Successful AstraZeneca lupus study bodes well for ImmuPharma’s Lupuzor™ – Sept 2019 Tim Franklin, ImmuPharma’s Chief Operating Officer talks to Proactive Investor on the forthcoming meeting in December between the Company’s partner Avion and the FDA, to discuss the international Phase 3 Lupus clinical trial – 25th November 2020 Tim McCarthy talks to Proactive Investor on 2 February 2018 Tim McCarthy talks to Proactive Investors – 6th February 2017 Tim McCarthy updates on Phase III study – 17th May 2017 Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor following the recent Corporate Update, outlining the broadening of the portfolio and re-emphasising the Board’s focus on delivering near term shareholder value on its key assets including moving Lupuzor into its Phase 3 trial Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the recent Company ‘Corporate Update’, the refocused product development portfolio and the positive corporate structure changes – 4 October 2021 Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the successful £3.55m fundraising, giving validation of new corporate strategy from Lupuzor™ partner Avion Pharmaceuticals Tim McCarthy, Chairman of ImmuPharma – 17th May 2017 Tim McCarthy, Chairman of ImmuPharma #IMM – 26th January 2017 Tim McCarthy, Chairman of ImmuPharma talks to Vox Markets on the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones – 13 December 2019 Tim McCarthy, Chairman of ImmuPharma, provides his first corporate update via the Investor Meet Company platform on 7 April 2020. Tim McCarthy, Chairman of ImmuPharma, talks to Proactive Investor about the first significant investment from two US healthcare specialist funds and ongoing news flow – 15 June 2020 Tim McCarthy, ImmuPharma’s Chairman, talks to Proactive Investors on the transformational Lupuzor™ licensing deal with US Avion Pharmaceuticals Vox market audio interview with Immupharma Chairman Tim McCarthy – 19th April 2018 Vox Markets interview Tim McCarthy, Chairman of ImmuPharma (IMM) – July 2019 Vox markets interview with Tim McCarthy – Nov 2019 Vox Markets Podcast – 18th September Vox markets podcast – July 2019 Vox Markets podcast featuring an interview with Dr Navid Malik Executive Director at The Life Sciences Division – Sept 2019 Vox markets podcast with Tim McCarthy – May 2019
Cookies This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy I Accept 